Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31357490 | 0.82 | RAB9A (0.64) | RAB9AMAPTALDH1A1NPC1VNN1 | |
| SCHEMBL10668250 | 0.80 | GSK3B (0.58) | GSK3BRAB9AMAPTALDH1A1CA1 | |
| SCHEMBL28042798 | 0.80 | RAB9A (0.55) | GSK3BRAB9AMAPTALDH1A1CA1 | |
| SCHEMBL1146988 | 0.79 | RAB9A (0.71) | GSK3BRAB9AMAPTALDH1A1CA1 | |
| SCHEMBL11983785 | 0.78 | GSK3B (0.70) | GSK3BRAB9AMAPTALDH1A1CA1 | |
| SCHEMBL3444279 | 0.77 | GSK3B (0.54) | GSK3BRAB9AMAPTALDH1A1CA1 | |
| SCHEMBL863102 | 0.76 | ESR2 (0.59) | RAB9AMAPTALDH1A1CA1CA2 | |
| SCHEMBL319223 | 0.76 | GSK3B (0.68) | GSK3BRAB9AMAPTALDH1A1CA1 | |
| SCHEMBL7290567 | 0.76 | CA1 (0.54) | RAB9AMAPTALDH1A1CA1CA2 | |
| SCHEMBL2064455 | 0.76 | NPC1 (0.58) | GSK3BRAB9AMAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023073090-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2023-05-04 | — | — | WO | disclosed |
| EP-2590956-B1 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (S1P) receptors | MERCK SERONO SA (CH) | 2016-05-04 | — | — | EP | disclosed |
| CN-103097365-B | 5- (biphenyl-4-yl) -3-phenyl-1, 2, 4-oxadiazolyl derivatives as ligands on sphingosine-1-phosphate (S1P) receptors | MERCK SERONO S.A. (CH) | 2016-02-24 | — | — | CN | disclosed |
| US-9029405-B2 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(SIP)receptors | MERCK SERONO S.A. (CH) | 2015-05-12 | — | — | US | disclosed |
| EP-2590956-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | Merck Serono S.A. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | MERCK SERONO S.A. (CH) | 2013-05-09 | — | — | US | disclosed |
| CN-103097365-A | 5- (biphenyl-4-yl) -3-phenyl-1, 2, 4-oxadiazolyl derivatives as ligands on sphingosine-1-phosphate (S1P) receptors | MERCK SERONO SA | 2013-05-08 | — | — | CN | disclosed |
| WO-2012004287-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | MERCK SERONO S.A. (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-0166609-A2 | Aryl derivatives of heterobicyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | S1PR1, S1PR5, S1PR2 | GSK3B 614/4885RAB9A 3357/4885MAPT 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.